Circulating tumor cell clusters more likely to cause metastasis than single cells

(Press-News.org) Circulating tumor cell (CTC) clusters – clumps of from 2 to 50 tumor cells that break off a primary tumor and are carried through the bloodstream – appear to be much more likely to cause metastasis than are single CTCs, according to a study from investigators at the Massachusetts General Hospital (MGH) Cancer Center. Their report in the August 28 issue of Cell also suggests that a cell adhesion protein binding CTC clusters together is a potential therapeutic target.

"While CTCs are considered to be precursors of metastasis, the significance of CTC clusters, which are readily detected using devices developed here at MGH, has remained elusive," says Shyamala Maheswaran, PhD, of the MGH Cancer Center, co-senior author of the Cell paper. "Our findings that the presence of CTC clusters in the blood of cancer patients is associated with poor prognosis may identify a novel and potentially targetable step in the blood-borne spread of cancer."

In their experiments the team used two versions of a microfluidic device called the CTC-Chip – both developed at the MGH Center for Engineering in Medicine – that captures CTCs from blood samples in ways that make the cells accessible for scientific testing. One version – the HBCTC-Chip – can efficiently capture extremely rare CTCs in a blood sample. Another version, the CTC-iChip, rapidly isolates CTCs in a way that does not rely on preidentified tumor antigens, allowing capture of cells with gene expression patterns that may be missed by the antibodies used in the HBCTC-Chip.

A series of experiments in animal models of breast cancer revealed that:

CTC clusters are made up of cells that probably were adjacent to each other in the primary tumor, not cells that proliferated after entering the bloodstream.

Although CTC clusters make up only 2 to 5 percent of all CTCs, they contributed to around half of lung metastases resulting from implanted breast tumors, indicating a metastatic potential 23 to 50 times greater than single CTCs.

CTC clusters injected into mice survived in greater numbers than did single CTCs, and metastases developing from clusters led to significantly reduced survival.

CTC clusters disappear from the animals' bloodstreams more rapidly than do single CTCs, probably because they become lodged in capillaries where they give rise to metastases.

Analysis of blood samples taken at several points in time from a group of patients with different forms of advanced metastatic breast cancer found CTC clusters in the blood of 35 percent of patients and that the survival of those with more clusters in their blood was significantly reduced. Similar analysis of samples from a group of prostate cancer patients also found an association between the presence of CTC clusters and dramatically reduced survival.

RNA sequencing of both single and clustered CTCs from breast cancer patients identified several genes expressed at elevated levels in CTC clusters, one of which – a protein called plakoglobin – also was overexpressed in the primary tumors of patients with reduced survival. Analysis of blood and tissue samples from one patient revealed that plakoglobin was expressed in CTC clusters but not single CTCs and also was expressed in some portions of both the primary tumor and metastases. Plakoglobin is a component of two important structures involved in cell-to-cell adhesion, and the investigators found that suppressing its expression caused CTC clusters to fall apart, reducing their metastatic potential, and also disrupted cell-to-cell contact between breast cancer cells but not normal breast tissue.

"It is possible that therapeutically targeting plakoglobin or pathways involved in cell-to-cell adhesion within cancer cells could be clinically useful, especially in patients in whom CTC clusters are found," says Nicola Aceto, PhD, of the MGH Cancer Center and lead author of the Cell paper. "We need to investigate that possibility along with determining whether further characterization of both single CTCs and CTC clusters will provide further insight into differences in their biology, drug responsiveness and their contribution to the process of metastasis."

INFORMATION:

Daniel Haber, MD, PhD, director of the MGH Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School (HMS), is co-senior author of the Cell paper along with Maheswaran, an associate professor of Surgery at HMS. Mehmet Toner, PhD, director of the BioMicroElectroMechanical Systems Resource Center in the MGH Center for Engineering in Medicine and the Benedict Professor of Surgery at HMS is also a coauthor of the report.

In 2011 the MGH entered a collaborative agreement with Janssen Diagnostics to establish a center of excellence in CTC research. Additional support for the current study includes a "dream team" grant from Stand Up to Cancer and grants from the Breast Cancer Research Foundation, the National Foundation for Cancer Research, the National Institutes of Health, Susan G. Komen for the Cure, ESSCO Breast Cancer Foundation and the Howard Hughes Medical Institute.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $785 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.